What is Alexion Pharmaceuticals' stock symbol?
Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."
Where is Alexion Pharmaceuticals' stock going? Where will Alexion Pharmaceuticals' stock price be in 2017?
22 analysts have issued 12 month price objectives for Alexion Pharmaceuticals' shares. Their predictions range from $120.00 to $221.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $170.33 in the next twelve months.
When will Alexion Pharmaceuticals announce their earnings?
Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.
What are analysts saying about Alexion Pharmaceuticals stock?
Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:
- RBC Capital Markets analysts commented, "Two new Phase III trials of ALXN1210 in PNH and aHUS announced; subQ formulation with 'new higher concentration formulation' mentioned on the call: On the second page of today's press release, Alexion disclosed the initiation of a new Phase III switch study of '1210 in PNH: 192 PNH patients who have been treated with Soliris will be enrolled into this openlabel, randomized (1:1), 26-week study. The study will compare patients receiving Q8W dosing of '1210 and Soliris on 3 weight cohorts. The primary endpoint is % change in LDH levels. Enrollment for this study will begin in 2Q17. In addition, a second Phase III trial of F1210 in pediatric aHUS is planned to start in 2Q17. Management reiterated that the target approval timing for ALXN1210 is late 2018 or early 2019. In addition, enrollment of 40 healthy volunteers in the Phase I trial of subcutaneous ALXN1210 was completed in 4Q16' Adjusting PT following SBC-103 discontinuation/pipeline update: We have updated our model and have removed SBC-103 from our revenue model. We've also removed ALXN1007 for APS and GI-GvHD from our PAT revenue model, since it's no longer being mentioned in ALXN's slides. Our price target goes to $177 from $187." (2/17/2017)
Cowen and Company analysts commented, "Alexion reported Q4 revenues of $831MM (+19% Y/Y, vs. consensus of $836MM)." (2/16/2017)
According to Zacks Investment Research, "Alexion’s top-line continues to be driven by continued growth in Soliris across geographies, robust launch momentum of Strensiq in initial countries, and early contribution from the launch of Kanuma in the U.S. and Germany. In fact, the company is viewing Strensiq as a key growth driver in 2017 and beyond. Alexion also updated its 2016 guidance for revenues and earnings. The company expects to meet the high end of both the previously guided projections. Meanwhile, Alexion has quite a few candidates in its pipeline and is working on expanding Soliris’ label. However, the company has suffered some pipeline-related setbacks of late. Moreover, ongoing focus on drug pricing and sudden departure of its key executives in the middle of an ongoing internal probe into the sales practices related to Soliris are concerns. In fact, shares of Alexion have underperformed the Medical-Biomedical/Genetics industry year to date." (12/28/2016)
Piper Jaffray Companies analysts commented, "2017 outlook strong. CNC’s initial 2017 guidance for adjusted diluted EPS is $4.40-4.85, which is below our prior $5.00 estimate (now reduced to $4.90) primarily because the company assumes a 1.5% lower margins ($0.20 per share) than it earned in 2016, albeit on higher revenue. This translates into guidance of $4.60-$5.05 before these lower assumptions. Revenue guidance is $46-46.8 billion, in line with our $46.2 billion estimate, which assumes 0%-1% Medicaid rate increases and Medicare Advantage expansion in four states." (12/23/2016)
Who owns Alexion Pharmaceuticals stock?
Alexion Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (12.58%), State Street Corp (4.72%), Sands Capital Management LLC (2.49%), Brown Advisory Inc. (1.45%), Franklin Resources Inc. (0.92%) and Temasek Holdings Private Ltd (0.55%). Company insiders that own Alexion Pharmaceuticals stock include Alvin S Parven, Ann M Veneman, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Martin Mackay, Saqib Islam and Vikas Sinha.
Who sold Alexion Pharmaceuticals stock? Who is selling Alexion Pharmaceuticals stock?
Alexion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Brown Advisory Inc., Marshall Wace LLP, Calamos Advisors LLC, Tudor Investment Corp Et Al, Raymond James Financial Services Advisors Inc., Guggenheim Capital LLC, DSM Capital Partners LLC and TCW Group Inc.. Company insiders that have sold Alexion Pharmaceuticals stock in the last year include Alvin S Parven, Carsten Thiel, Clare Carmichael, David Hallal, Edward Miller, Heidi L Wagner, John B Moriarty, Julie O'neill, Leonard Bell, Martin Mackay and Vikas Sinha.
Who bought Alexion Pharmaceuticals stock? Who is buying Alexion Pharmaceuticals stock?
Alexion Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., State Street Corp, Sands Capital Management LLC, Alyeska Investment Group L.P., Asset Management One Co. Ltd., Fred Alger Management Inc. and AMF Pensionsforsakring AB.
How do I buy Alexion Pharmaceuticals stock?
Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alexion Pharmaceuticals stock cost?
One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $130.44.